



Pathogenic *TP53* mutations influence chemotherapy response and survival rate of patients with HPV-negative oral carcinomas

Uticaj patogenih *TP53* mutacija na preživljavanje i odgovor na hemioterapiju bolesnika sa HPV-negativnim oralnim karcinomima

Saša Jović*†, Ružica Kozomara*†, Srboljub Stošić*†, Stevo Jovandić‡, Katarina Zeljić§, Gordana Šupić†‡

Military Medical Academy, *Clinic for Maxillofacial Surgery, ‡Institute for Medical Research, Belgrade, Serbia; †University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia; §University of Belgrade, Faculty of Biology, Belgrade, Serbia

Abstract

Background/Aim. Oral squamous cell carcinoma (OSCC) is the most common tumor type of head and neck carcinomas, characterized by a high recurrence rate and patients' poor survival. Further elucidation of the function and regulation of the *TP53*, a pivotal tumor suppressor gene, would provide advances in predicting the clinical behavior, prognosis, and chemotherapy response of OSCC patients. Thus, we investigated the association of *TP53* gene mutations with survival and response to cisplatin chemotherapy in human papilloma virus (HPV)-negative OSCC patients. **Methods.** The potential clinical relevance of *TP53* mutations was analyzed in 82 patients with HPV-negative OSCC. All patients underwent radiotherapy, and 25 patients received cisplatin chemotherapy. A negative HPV status was determined by type-specific polymerase chain reaction (PCR) for high-risk HPV 16, 18, 31, and 33. Targeted sequencing of *TP53* exons 4–8 was assessed by Sanger sequencing. **Results.** Of 82 HPV-negative OSCC patients, 49

(59.79%) had *TP53* mutations, and 26 patients (31.7%) carried pathogenic *TP53* mutations. Patients with pathogenic *TP53* mutations had significantly reduced overall survival ($p = 0.009$). Recurrence status, but not *TP53* mutations, was an independent marker of poor survival in our cohort [hazard ratio (HR) = 4.733, 95% confidence interval (95% CI): 2.027–11.053, $p = 0.0001$]. In the sub-cohort of patients who underwent cisplatin-based chemotherapy, pathogenic *TP53* mutations were predictors of poor response to chemotherapy ($p = 0.026$). **Conclusion.** Our findings indicate that pathogenic *TP53* mutations in HPV-negative OSCC tumors could be a prognostic marker of patients' reduced overall survival. In addition, pathogenic *TP53* mutations in HPV-negative OSCC could be a marker of poor chemotherapy response of OSCC patients.

Key words:

carcinoma, squamous cell; drug therapy; genes, tumor suppressor; head and neck neoplasms; mutation; prognosis; radiotherapy; survival rate.

Apstrakt

Uvod/Cilj. Oralni planocelularni karcinom (OPCK) je najčešći tip karcinoma glave i vrata, koji se odlikuje visokom stopom recidiva i lošim preživljavanjem bolesnika. Dalje razjašnjenje uloge i regulacije *TP53*, ključnog tumor supresorskog gena, omogućilo bi napredak u predviđanju toka, prognoze i hemioterapijskog odgovora obolelih od OPCK. Zbog toga smo istražili povezanost mutacija gena *TP53* sa preživljavanjem i odgovorom na hemioterapiju cisplatinom bolesnika sa HPV-negativnim OPCK. **Metode.** Potencijalni klinički značaj mutacija *TP53* analiziran je kod 82 bolesnika sa HPV-negativnim

OPCK. Svi bolesnici su bili podvrgnuti radioterapiji, a 25 bolesnika primilo je hemioterapiju cisplatinom. Negativni HPV status utvrđen je tip-specifičnom metodom *polymerase chain reaction* (PCR), za visoko rizične HPV 16, 18, 31 i 33. Ciljno sekvenciranje *TP53* egzona 4–8 rađeno je Sanger kapilarnim sekvenciranjem. **Rezultati.** Od 82 HPV-negativnih OPCK bolesnika, njih 49 (59,79%) imalo je *TP53* mutaciju, a 26 (31,7%) bolesnika je imalo patogene *TP53* mutacije. Bolesnici sa patogenim mutacijama *TP53* imali su značajno smanjeno celokupno preživljavanje ($p = 0,009$). Status recidiva, ali ne i *TP53* mutacije, bio je nezavisni marker lošeg preživljavanja bolesnika u našoj studiji [hazard ratio (HR) = 4,733, 95% confidence interval (95% CI): 2,027–11,053; $p = 0,0001$]. U

podgrupi bolesnika koji su bili podvrgnuti hemioterapiji cisplatinom, patogene *TP53* mutacije bile su prediktori slabog odgovora na hemioterapiju ($p = 0,026$). **Zaključak.** Naši nalazi ukazuju da bi patogene *TP53* mutacije u HPV-negativnim OPCK tumorima mogle biti prognostički marker smanjenog ukupnog preživljavanja bolesnika. Pored toga, patogene *TP53* mutacije u HPV-

negativnom OPCK mogu biti marker lošeg odgovora tih bolesnika na hemioterapiju.

Ključne reči:

karcinom, planocelularni; lečenje lekovima; geni, tumor-supresori; glava i vrat, neoplazme; mutacija; prognoza; radioterapija; preživljavanje, stepen.

Introduction

Oral squamous cell carcinoma (OSCC) is the most common tumor type of head and neck carcinomas, characterized by a high recurrence rate and patients' poor survival. This malignancy is the sixth most common cancer worldwide in men and eighth in women in developed countries, while in developing countries, it is the third most common cancer in men and fourth in women, which affects approximately 600,000 new patients every year worldwide ¹. Oral carcinogenesis is a multi-step process that encompasses an accumulation of genetic and epigenetic changes which lead to the disruption of the various signaling pathways controlling the cell cycle, proliferation, apoptosis, senescence, and DNA ². Genetic changes are progressively accumulated, and the inactivation of tumor suppressor genes by point mutations, deletions, and gene rearrangement is one of the key changes for malignant transformation. Known etiological factors for developing OSCC are predominantly smoking, alcohol intake, and poor oral hygiene. Approximately 20–30% of OSCC cases can be associated with tobacco smoking and 7–19% with heavy alcohol drinking, which increases the risk of oral cavity cancer 2–3 times ³. One of the most important advances in oral carcinogenesis in recent decades is the evidence of an association between oral cancer and some types of human papillomavirus (HPV) infection, predominantly HPV16 ⁴.

Gene coding for protein p53 (*TP53*) is one of the most prominent tumor suppressor genes located on the short arm of chromosome 17 (17p13.1) ⁵. Protein p53 is a key factor in a signaling pathway that helps the cell to recover from DNA damage ⁶. Upon DNA damage, the wild type (WT) p53 arrests the cell cycle in the G1 phase prohibiting transition to the S phase until the damage is repaired. Additionally, throughout the retinoblastoma tumor suppressor pathway, p53 can direct cells to a state of permanent cell cycle arrest or induce pro-apoptotic genes cellular senescence ⁷. *TP53* is one of the most frequently mutated human genes in more than 50% of cancers. Germline *TP53* mutations cause Li-Fraumeni syndrome, a rare autosomal, hereditary disorder predisposing to sarcoma, breast cancer, leukemia, and adrenal gland carcinoma ⁸.

TP53 mutations are early alterations during oral carcinogenesis, and more than 25,000 mutations have been discovered so far ⁹. Most of them (70%) are missense mutations in the coding regions ¹⁰, where approximately 30% of mutations occur in exon 7 and exon 8, known as mutation hot spots. These exons code for the DNA binding domain, preventing the p53 binding to the promoter of target genes ¹¹. Common

TP53 codon 72 gene polymorphism in this domain produces two functional variants of p53 – p53P (proline) and p53A (arginine), which could reduce its ability to mediate apoptosis and cell cycle arrest and could, therefore, affect the survival and chemotherapy response ¹². A number of studies reported inconsistent findings regarding whether the *TP53* mutations and codon 72 polymorphism influence survival and chemotherapy response in OSCC patients ¹³.

Inactivation of WT p53 can also be achieved throughout HPV E6 protein ¹¹. HPV-positive oropharyngeal cancer cells have a different molecular profile from HPV-negative oropharyngeal cancer cells, where HPV-negative oropharyngeal cancers have a more frequent loss of heterozygosity of 3p, 9p, or 17p chromosomal regions ¹⁴. HPV-negative oropharyngeal cancers have at least two times more mutations compared to HPV-positive tumors ^{15, 16}, and worse outcome ¹⁷, indicating the necessity of molecular characterization of p53 in HPV-negative OSCC.

Further elucidation of the function and regulation of p53 in HPV-negative OSCC would provide advances in predicting the clinical behavior, prognosis, and patients' chemotherapy response. Finding the potential markers that could predict tumor response to chemotherapy, developing new strategies with therapeutics targeting different pathways that will override the resistance, and tumor molecular profiling would provide an individualized approach to the treatment modalities of OSCC patients.

Methods

The current study was approved by the Ethics Committee of the Military Medical Academy (No 162/2019, from December 26, 2019), according to the Helsinki Declaration (1964). The study group included 82 OSCC patients, Caucasians of the same ethnicity. All patients were diagnosed and subsequently operated on at the Clinic for Maxillofacial Surgery, Military Medical Academy, Belgrade, Serbia, between 2012 and 2020. All of them were operated on and received radiotherapy (60 Gy in 2 Gy dose per day), and 25 of the patients received cisplatin therapy in a dosage of 100 mg/m² of body surface area in one-week cycles. The face-to-face interviews were conducted to obtain demographic data. The evaluation of lymph node status and the tumor, node, metastasis (TMN) classification were determined by an experienced pathologist in accordance with the classification of the American Head and Neck Society and American Joint Committee on Cancer (AJCC Cancer Staging Manual 8th Edition, 2018). Of 82 OSCC patients, 35 (42.7%) were under 58 years of age, 58 (70.7%) were male,

57 (69.5%) had a history of alcohol abuse, 19 (23.2%) had stage II OSCC while 63 (76.8%) had advanced-stage tumors.

DNA isolation and HPV analysis

OSCC tissue samples were stored at -20°C until DNA extraction. Genomic DNA was isolated by the TRI Reagent® (Sigma-Aldrich, USA) according to the manufacturer's protocol. DNA samples were stored at -20°C until further analysis. Type-specific polymerase chain reaction (PCR) was assessed for high-risk HPV types 16, 18, 31, and 33.

TP53 Sanger sequencing

Targeted sequencing of p53 exons 4-8 was assessed by Sanger sequencing on ABI 3130 automated sequencer (Applied Biosystems, USA). The primers flanking exons 4-8 were retrieved from the IARC TP53 database. PCR reactions were performed using the Platinum Taq DNA Polymerase PCR kit (Life Technologies). Amplicons were sequenced using the BigDye terminator cycle sequencing kit. Sequencing traces were analyzed with GeneScreen (<http://dna.leeds.ac.uk/genescreen/>) followed by visual inspection, with reference to the human genome reference sequence build hg19/GRCh37 (<http://genome.ucsc.edu>).

TP53 mutation classification according to its clinical significance

To provide information on pathogenic TP53 mutations, genetic variants with clinical significance, we assessed the ClinVar database of the NCBI (National Center for Biotechnology Information) and a web server application Simple ClinVar¹⁸.

TP53 mutations were classified as pathogenic and non-pathogenic mutations according to the ClinVar database, Simple ClinVar¹⁸, and previous studies on head and neck carcinoma^{19, 20}. Missense, stop-gain, in-frame insertions/deletions, frameshift, and splice site TP53 mutations with pathogenic and likely pathogenic significance, and criteria provided by multiple or single submitters, reviewed by expert panels or given in practice guidelines, were classified as pathogenic mutations. On the other hand, likely benign, protective, or with uncertain significance were classified as non-pathogenic mutations.

Statistical analysis

Obtained data were analyzed by SPSS 20.0 software (IBM Inc., Chicago, IL, USA). Contingency tables were assessed by χ^2 -test or Fisher's exact test. Overall survival was calculated from the date of diagnosis until death from any cause. Kaplan-Meier survival curves were compared using the log-rank test. Cox proportional hazard regression analysis was performed to estimate the hazard ratios (HR) with a 95% confidence interval (95% CI). Variables found significant in the univariate analysis, including those with a significance level below 20%, were subsequently analyzed in multivariate

Cox's regression. The Cox model was performed using the forward stepwise method, which removed variables with $p < 0.1$. The associations were considered as significant when p -values were less than 0.05.

Results

Association of p53 gene mutations, pathogenic p53 mutations, and polymorphism p72 with demographic and clinicopathological features of HPV-negative OSCC patients

Eighty-two HPV-negative OSCC samples were screened for TP53 mutations in exons 4-8, and mutations were found in a total of 49 (59.8%) patients. TP53 mutations were classified as pathogenic and non-pathogenic, as previously suggested^{19, 20}. Pathogenic TP53 mutations were detected in 26 of 82 (31.7%) OSCC patients.

The association of TP53 gene mutations, pathogenic TP53 mutations, and polymorphism p72 with demographic and clinicopathological features of OSCC patients are presented in Table 1. No association was found between TP53 mutations or pathogenic TP53 mutations and sex or smoking. Pathogenic TP53 mutations were significantly associated with age ($p = 0.005$) and high alcohol intake ($p = 0.009$). Locally advanced tumors did not have a statistically higher TP53 mutation rate or pathogenic TP53 mutations compared to early-stage OSCC. Mutations in exon 4 of the p53 gene were significantly associated with histological and nuclear grade ($p = 0.012$ and $p = 0.032$, respectively), while mutations in exon 7 were associated with smoking status ($p = 0.017$).

Association of TP53 gene mutations, pathogenic TP53 mutations, and polymorphism p72 with overall survival of OSCC patients

Overall survival (OS) curves were assessed by the Kaplan-Meier analysis and compared by the log-rank test. HPV-negative OSCC patients with mutated TP53 tended to have worse survival ($p = 0.085$) as opposed to patients without TP53 mutations. However, OSCC patients with pathogenic mutations in TP53 had significantly reduced OS ($p = 0.009$, Figure 1). Non-pathogenic TP53 mutations were not associated with OS of OSCC patients ($p = 0.785$, log-rank test). No significant difference was observed in OS between OSCC patients with different genotypes of p72 polymorphism ($p = 0.905$, log-rank test).

In the subgroup of 25 patients who received chemotherapy in our cohort, when all TP53 mutations were taken into account, TP53 mutation status was not associated with chemotherapy response ($p = 0.641$, Figure 2A). However, OS in patients who had received cisplatin chemotherapy was significantly shorter for those with pathogenic p53 mutations compared to patients with WT P53 ($p = 0.026$, Figure 2B). Non-pathogenic TP53 mutations in patients who had received cisplatin chemotherapy were not related to OS in our cohort

Table 1

Association of p53 gene mutations and polymorphism p72 with demographic and clinicopathological features of OSCC patients

| Variables | Total (n) | All TP53 | | | | | | | | | | | | p72 rs1042522 | | | Pathogenic TP53 mutations | |
|---------------------|-----------|-----------|----|--------------|----|-------|----|-------|----|-------|----|--------------|----|---------------|-----|-----|---------------------------|----|
| | | Mutations | | E4 | | E5 | | E6 | | E7 | | E8 | | p72 rs1042522 | | | | |
| | | + | - | + | - | + | - | + | - | + | - | + | - | WT | het | mut | + | - |
| Sex | | | | | | | | | | | | | | | | | | |
| male | 58 | 35 | 23 | 30 | 28 | 6 | 52 | 16 | 42 | 2 | 56 | 16 | 42 | 35 | 22 | 1 | 16 | 42 |
| female | 24 | 14 | 10 | 13 | 11 | 1 | 23 | 10 | 14 | 0 | 24 | 4 | 20 | 11 | 11 | 2 | 10 | 14 |
| <i>p</i> | | 0.866 | | 0.840 | | 0.362 | | 0.357 | | 0.295 | | 0.479 | | 0.231 | | | 0.231 | |
| Age (years), median | | | | | | | | | | | | | | | | | | |
| < 58 | 35 | 23 | 12 | 17 | 18 | 4 | 31 | 17 | 18 | 1 | 34 | 9 | 26 | 17 | 15 | 3 | 17 | 18 |
| ≥ 58 | 47 | 21 | 26 | 26 | 21 | 3 | 44 | 9 | 38 | 1 | 46 | 11 | 36 | 29 | 18 | 0 | 9 | 36 |
| <i>p</i> | | 0.342 | | 0.545 | | 0.419 | | 0.832 | | 0.810 | | 0.563 | | 0.093 | | | 0.005 | |
| Smoking | | | | | | | | | | | | | | | | | | |
| never | 25 | 15 | 10 | 15 | 10 | 1 | 24 | 7 | 18 | 0 | 25 | 7 | 18 | 13 | 12 | 0 | 7 | 18 |
| ever | 57 | 34 | 23 | 28 | 29 | 6 | 51 | 19 | 38 | 2 | 55 | 13 | 44 | 25 | 32 | 0 | 19 | 38 |
| <i>p</i> | | 0.976 | | 0.364 | | 0.330 | | 0.343 | | 0.614 | | 0.017 | | 0.375 | | | 0.798 | |
| High alcohol intake | | | | | | | | | | | | | | | | | | |
| no | 57 | 33 | 24 | 30 | 27 | 5 | 52 | 13 | 44 | 1 | 56 | 14 | 43 | 33 | 23 | 1 | 13 | 44 |
| yes | 25 | 16 | 9 | 13 | 12 | 2 | 23 | 13 | 12 | 1 | 24 | 6 | 19 | 13 | 10 | 2 | 13 | 12 |
| <i>p</i> | | 0.604 | | 0.958 | | 0.908 | | 0.544 | | 0.957 | | 0.419 | | 0.375 | | | 0.009 | |
| Histological grade | | | | | | | | | | | | | | | | | | |
| 1 | 61 | 34 | 27 | 27 | 34 | 6 | 55 | 16 | 45 | 1 | 60 | 15 | 46 | 39 | 19 | 3 | 16 | 45 |
| 2/3 | 21 | 15 | 6 | 16 | 5 | 1 | 20 | 10 | 11 | 1 | 20 | 5 | 16 | 7 | 14 | 0 | 10 | 11 |
| <i>p</i> | | 0.206 | | 0.012 | | 0.473 | | 0.424 | | 0.943 | | 0.342 | | 0.014 | | | 0.069 | |
| Nucleus grade | | | | | | | | | | | | | | | | | | |
| 1 | 58 | 32 | 26 | 26 | 32 | 6 | 52 | 17 | 41 | 1 | 57 | 15 | 43 | 36 | 19 | 3 | 17 | 41 |
| 2/3 | 24 | 17 | 7 | 17 | 7 | 1 | 23 | 9 | 15 | 1 | 23 | 5 | 19 | 10 | 14 | 0 | 9 | 15 |
| <i>p</i> | | 0.188 | | 0.032 | | 0.362 | | 0.514 | | 0.629 | | 0.220 | | 0.072 | | | 0.468 | |
| Nodal status | | | | | | | | | | | | | | | | | | |
| - | 19 | 14 | 5 | 10 | 9 | 2 | 17 | 7 | 12 | 0 | 19 | 5 | 14 | 9 | 10 | 0 | 7 | 12 |
| + | 63 | 35 | 28 | 29 | 34 | 5 | 58 | 19 | 44 | 2 | 61 | 15 | 48 | 37 | 23 | 3 | 19 | 44 |
| <i>p</i> | | 0.158 | | 0.614 | | 0.723 | | 0.432 | | 0.824 | | 0.865 | | 0.336 | | | 0.583 | |
| Tumor size | | | | | | | | | | | | | | | | | | |
| T1/2 | 60 | 37 | 23 | 29 | 31 | 6 | 54 | 21 | 39 | 2 | 58 | 15 | 45 | 31 | 26 | 3 | 21 | 39 |
| T3/4 | 22 | 12 | 10 | 14 | 8 | 1 | 21 | 5 | 17 | 0 | 22 | 5 | 17 | 19 | 7 | 0 | 5 | 17 |
| <i>p</i> | | 0.560 | | 0.219 | | 0.434 | | 0.386 | | 0.832 | | 0.137 | | 0.299 | | | 0.290 | |
| Tumor stage | | | | | | | | | | | | | | | | | | |
| II | 19 | 13 | 6 | 8 | 11 | 3 | 16 | 5 | 14 | 1 | 18 | 4 | 15 | 8 | 10 | 1 | 5 | 14 |
| III | 63 | 36 | 27 | 35 | 28 | 4 | 59 | 21 | 42 | 1 | 62 | 16 | 47 | 38 | 23 | 2 | 21 | 42 |
| <i>p</i> | | 0.380 | | 0.303 | | 0.197 | | 0.363 | | 0.699 | | 0.387 | | 0.372 | | | 0.564 | |

OSCC – oral squamous cell carcinoma; n – total number of patients; E – exon; WT – wild type; het – heterozygosity; mut – mutation. Statistically significant values are bolded.





Fig. 1 – Kaplan-Meier curves for overall survival based on the TP53 mutation status in a total cohort of 82 HPV-negative OSCC patients: A) Survival comparison between all TP53 mutations (mut.) and wild type (WT) TP53; B) Comparison of pathogenic TP53 mutations and WT TP53. OSCC – oral squamous cell carcinoma.



**Fig. 2 – Associations between *TP53* mutations and survival outcome of the subgroup of 25 OSCC patients who received platinum-based chemotherapy: A) Survival comparison between all *TP53* mutations (mut.) and wild type (WT) *TP53*; B) Comparison of pathogenic *TP53* mutations and WT *TP53*.
OSCC – oral squamous cell carcinoma.**

($p = 0.453$, log-rank test). These findings indicate that the response to chemotherapy was associated with the type of p53 mutation and that the patients with pathogenic *TP53* mutations were resistant to platinum-based chemotherapy, as opposed to the patients with WT *TP53*.

The Cox regression analysis demonstrated that high alcohol intake, stage, tumor size, nodal status, and recurrences are highly associated with hazard risk (Table 2). While patients with *TP53* mutations had increased but insignificant hazard risk [HR=1.747, 95% CI (0.907–3.366), $p = 0.096$], patients with pathogenic *TP53* mutations had significantly

increased risk of poor survival [HR = 2.230, 95% CI (1.186–4.194), $p = 0.013$]. Variables found to be statistically significant, according to the univariate analysis, including the variables with a significance level below 20%, were subsequently analyzed in multivariate Cox hazards regression analysis. The multivariate analysis revealed that the recurrences persisted as an independent prognostic factor in our cohort [HR = 4.733, 95% CI (2.027–11.053), $p = 0.0001$] (Table 2). The list of detected *TP53* mutations and their classification according to clinical significance, assessed by the ClinVar database and Simple ClinVar web server, is given in Table 3.

Table 2

Cox proportional hazards regression analysis, according to overall survival of OSCC patients

| Cox regression analysis | Demographic or pathological features | Overall survival | |
|-------------------------|--------------------------------------|-------------------------|---------------|
| | | HR (95% CI) | <i>p</i> |
| | Sex | 0.660 (0.335–1.300) | 0.230 |
| | Age | 0.605 (0.332–1.102) | 0.100 |
| | Smoking | 1.682 (0.804–3.519) | 0.167 |
| | High alcohol intake | 2.938 (1.610–5.360) | 0.0001 |
| | Nuclear grade | 1.245 (0.900–1.721) | 0.186 |
| | Histological grade | 1.270 (0.914–1.764) | 0.155 |
| Univariate analysis | Stage | 3.898 (1.388–10.947) | 0.010 |
| | Tumor size | 1.654 (1.189–2.302) | 0.003 |
| | Nodal status | 3.055 (1.199–7.786) | 0.019 |
| | Recurrences | 4.727 (2.108–10.597) | 0.0001 |
| | All <i>TP53</i> mutations | 1.747 (0.907–3.366) | 0.096 |
| | Pathogenic <i>TP53</i> mutations | 2.230 (1.186–4.194) | 0.013 |
| | p72 SNP | 1.065 (0.645–1.759) | 0.806 |
| Multivariate analysis | Recurrences | 4.733 (2.027–11.053) | 0.0001 |

OSCC – oral squamous cell carcinoma; HR – hazard ratio; CI – confidence interval; SNP – single nucleotide polymorphism.

Statistically significant values are bolded.

Table 3
Data on TP53 mutations, assessed by the ClinVar database of the NCBI and a web server application Simple ClinVar¹⁸

| TP53 mutation name | Clinical significance (Last reviewed) | Condition(s) |
|---|---------------------------------------|---|
| NM_000546.5(TP53):c.215= (p.Pro72=) | Benign | Not specified |
| NM_000546.5(TP53):c.273G>A (p.Trp91Ter) | Pathogenic | Hereditary cancer-predisposing syndrome; Neoplasm of the ovary; Li-Fraumeni syndrome; Li-Fraumeni syndrome 1 |
| NM_001126114.2(TP53):c.560-11_560-8dup | Likely benign | Li-Fraumeni syndrome |
| NM_000546.5(TP53):c.820_821delGT (p.Val274Leuifs) | Pathogenic | Li-Fraumeni syndrome |
| NM_000546.5(TP53):c.896_909del (p.Leu299Hisfs) | Pathogenic | Not provided |
| NM_000546.5(TP53):c.273G>A (p.Trp91Ter) | Pathogenic | Li-Fraumeni syndrome; Not provided; Hereditary cancer-predisposing syndrome |
| NM_000546.5(TP53):c.380C>G (p.Ser127Cys) | Uncertain significance | Li-Fraumeni syndrome |
| NM_000546.5(TP53):c.384T>C (p.Pro128=) | Likely benign | Hereditary cancer-predisposing syndrome |
| NM_000546.5(TP53):c.389T>C (p.Leu130Pro) | Likely pathogenic | Hereditary cancer-predisposing syndrome |
| NM_000546.5(TP53):c.401T>G (p.Phe134Cys) | Likely pathogenic | Not provided; Hereditary cancer-predisposing syndrome |
| NM_000546.5(TP53):c.411G>C (p.Leu137=) | Likely benign | Hereditary cancer-predisposing syndrome |
| NM_000546.5(TP53):c.421T>A (p.Cys141Ser) | Likely pathogenic | Multiple myeloma; Squamous cell carcinoma of the head and neck; Lung adenocarcinoma; Squamous cell lung carcinoma; Acute myeloid leukemia; Renal cell carcinoma, papillary; Neoplasm of the brain; Neoplasm of the breast; Pancreatic adenocarcinoma; Neoplasm of the large intestine; Colorectal neoplasms; Malignant neoplasm of body of uterus; Adenocarcinoma of the prostate |
| NM_000546.5(TP53):c.428T>G (p.Val143Gly) | Uncertain significance | Hereditary cancer-predisposing syndrome |
| NM_000546.5(TP53):c.517G>T (p.Val173Leu) | Pathogenic | Liver cancer; Malignant melanoma of skin; Squamous cell carcinoma of the head and neck; Small cell lung cancer; Lung adenocarcinoma; Li-Fraumeni syndrome; Neoplasm of the breast; Hepatocellular carcinoma; Pancreatic adenocarcinoma; Brainstem glioma; Neoplasm of the large intestine; Carcinoma of the esophagus; Colorectal neoplasms; Adrenocortical carcinoma; Adenocarcinoma of the stomach; Ovarian serous cystadenocarcinoma; Malignant neoplasm of body of the uterus |
| NM_000546.5(TP53):c.560-15A>C | Likely benign | Hereditary cancer-predisposing syndrome |
| NM_000546.5(TP53):c.578A>G (p.His193Arg) | Likely pathogenic | Liver cancer; Chronic lymphocytic leukemia; Squamous cell carcinoma of the head and neck; Small cell lung cancer; Lung adenocarcinoma; Li-Fraumeni syndrome; Squamous cell lung carcinoma; Acute myeloid leukemia; Not provided; Neoplasm of the brain, Neoplasm of the breast; Hepatocellular carcinoma; Hereditary cancer-predisposing syndrome; Pancreatic adenocarcinoma; Transitional cell carcinoma of the bladder; Brainstem glioma; Neoplasm of the large intestine, Carcinoma of the esophagus; Colorectal neoplasms; Papillary renal cell carcinoma, sporadic; Adenocarcinoma of the stomach; Ovarian serous cystadenocarcinoma; Malignant neoplasm of body of uterus; Adenocarcinoma of the prostate; Uterine carcinosarcoma |
| NM_000546.5(TP53):c.591G>A (p.Val197=) | Uncertain significance | Li-Fraumeni syndrome |
| NM_000546.5(TP53):c.592delG (p.Glu198Lysfs) | Pathogenic | Hereditary cancer-predisposing syndrome |
| NM_000546.5(TP53):c.599delA (p.Asn200Ilefs) | Pathogenic | Hereditary cancer-predisposing syndrome |
| NM_000546.5(TP53):c.642T>C (p.His214=) | Likely benign | Li-Fraumeni syndrome |
| NM_000546.5(TP53):c.678C>A (p.Gly226=) | Likely benign | Not specified |
| NM_000546.5(TP53):c.698A>G (p.His233Arg) | Uncertain significance | Not specified; Hereditary cancer-predisposing syndrome |

Table 3 (continued)

| | | |
|---|--|---|
| NM_000546.5(TP53):c.700T>C (p.Tyr234His) | Pathogenic | Liver cancer; Squamous cell carcinoma of the head and neck; Small cell lung cancer; Li-Fraumeni syndrome; Squamous cell lung carcinoma; Neoplasm of the breast; Glioblastoma; Hepatocellular carcinoma; Hereditary cancer-predisposing syndrome; Pancreatic adenocarcinoma; Transitional cell carcinoma of the bladder; Neoplasm of the large intestine; Carcinoma of the esophagus; Colorectal neoplasms; Adrenocortical carcinoma; Adenocarcinoma of the stomach; Ovarian serous cystadenocarcinoma; Adenocarcinoma of the prostate |
| NM_001126113.2(TP53):c.710T>A (p.Met237Lys) | Likely pathogenic | Squamous cell carcinoma of the head and neck; Lung adenocarcinoma; Squamous cell lung carcinoma; Neoplasm of the brain; Neoplasm of the breast; Pancreatic adenocarcinoma; Brainstem glioma; Neoplasm of the large intestine; Carcinoma of the esophagus; Colorectal neoplasms; Adenocarcinoma of the stomach, Ovarian serous cystadenocarcinoma; Malignant neoplasm of body of the uterus |
| NM_000546.5(TP53):c.712T>C (p.Cys238Arg) | Pathogenic | Liver cancer; Chronic lymphocytic leukemia; Multiple myeloma; Squamous cell carcinoma of the head and neck; Lung adenocarcinoma; Neoplasm of the brain; Neoplasm of the breast; Glioblastoma; Hepatocellular carcinoma; Hereditary cancer-predisposing syndrome; Pancreatic adenocarcinoma; Transitional cell carcinoma of the bladder; Neoplasm of the large intestine; Carcinoma of the esophagus; Colorectal Neoplasms; Uterine cervical neoplasms; Adenocarcinoma of the stomach; Ovarian serous cystadenocarcinoma; Malignant neoplasm of body of uterus; Uterine carcinosarcoma |
| NM_000546.5(TP53):c.718A>G (p.Ser240Gly) | Likely pathogenic | Li-Fraumeni syndrome |
| NM_000546.5(TP53):c.724T>C (p.Cys242Arg) | Likely pathogenic | Not provided |
| NM_000546.5(TP53):c.727A>C (p.Met243Leu) | Uncertain significance | Hereditary cancer-predisposing syndrome |
| NM_000546.5(TP53):c.728T>C (p.Met243Thr) | Conflicting interpretations of pathogenicity | Li-Fraumeni syndrome; Not specified; Hereditary cancer-predisposing syndrome |
| NM_000546.5(TP53):c.730G>A (p.Gly244Ser) | Pathogenic/Likely pathogenic | Liver cancer; Squamous cell carcinoma of the head and neck; Small cell lung cancer; Lung adenocarcinoma; Li-Fraumeni syndrome; Squamous cell lung carcinoma; Neoplasm of the brain; Glioblastoma; Hepatocellular carcinoma; Hereditary cancer-predisposing syndrome; Neoplasm of the large intestine; Carcinoma of the esophagus; Colorectal Neoplasms; Adenocarcinoma of the stomach; Ovarian serous cystadenocarcinoma, Malignant neoplasm of body of uterus; Uterine carcinosarcoma |
| NM_000546.5(TP53):c.734G>C (p.Gly245Ala) | Likely pathogenic | Liver cancer; Squamous cell carcinoma of the head and neck; Lung adenocarcinoma; Squamous cell lung carcinoma; Neoplasm of the brain; Neoplasm of the breast; Glioblastoma; Hepatocellular carcinoma; Pancreatic adenocarcinoma; Transitional cell carcinoma of the bladder; Brainstem glioma; Neoplasm of the large intestine; Carcinoma of the esophagus; Colorectal Neoplasm of the esophagus; Colorectal neoplasms; Adenocarcinoma of the stomach; Ovarian serous cystadenocarcinoma; Malignant neoplasm of body of uterus; Uterine carcinosarcoma |
| NM_000546.5(TP53):c.737T>G (p.Met246Arg) | Pathogenic | Not provided |
| NM_000546.5(TP53):c.770T>A (p.Leu257Gln) | Uncertain significance | Li-Fraumeni-like syndrome; Li-Fraumeni syndrome |
| NM_000546.5(TP53):c.782+12C>T | Benign/Likely benign | Li-Fraumeni syndrome 1; Not specified; Hereditary cancer-predisposing syndrome |
| NM_000546.5(TP53):c.782+14T>G | Likely benign | Hereditary cancer-predisposing syndrome |
| NM_000546.5(TP53):c.783-1G>A | Pathogenic/Likely pathogenic | Li-Fraumeni syndrome; Hereditary cancer-predisposing syndrome |
| NM_000546.5(TP53):c.785delG (p.Gly262Valfs) | Pathogenic | Not provided; Hereditary cancer-predisposing syndrome |
| NM_000546.5(TP53):c.789T>C (p.Asn263=) | Likely benign | Hereditary cancer-predisposing syndrome |
| NM_000546.5(TP53):c.794T>C (p.Leu265Pro) | Pathogenic/Likely pathogenic | Li-Fraumeni syndrome 1; Li-Fraumeni syndrome; Not provided; Hereditary cancer-predisposing syndrome |
| NM_000546.5(TP53):c.401T>G (p.Phe134Cys) | Likely pathogenic | Hereditary cancer-predisposing syndrome; Not provided |
| NM_000546.5(TP53):c.798A>T (p.Gly266=) | Likely benign | Hereditary cancer-predisposing syndrome |
| NM_000546.5(TP53):c.814G>T (p.Val272Leu) | Likely pathogenic | Medulloblastoma; Multiple myeloma; Squamous cell carcinoma of the head and neck; Li-Fraumeni syndrome; Lung adenocarcinoma; Renal cell carcinoma; papillary; Neoplasm of the breast; Hereditary cancer-predisposing syndrome; Pancreatic adenocarcinoma; Squamous cell carcinoma of the skin; Transitional cell carcinoma of the bladder; Neoplasm of the large intestine; Colorectal neoplasms; Adenocarcinoma of the stomach; Ovarian serous cystadenocarcinoma; Malignant neoplasm of body of the uterus |
| NM_000546.5(TP53):c.829T>C (p.Cys277Arg) | Likely pathogenic | Not provided |
| NM_000546.5(TP53):c.869G>A (p.Arg290His) | Uncertain significance | Li-Fraumeni syndrome; Li-Fraumeni syndrome not specified; Hereditary cancer-predisposing syndrome |
| NM_000546.5(TP53):c.890A>G (p.His297Arg) | Uncertain significance | Hereditary cancer-predisposing syndrome |
| NM_000546.5(TP53):c.904G>C (p.Gly302Arg) | Uncertain significance | Li-Fraumeni syndrome |
| NM_000546.5(TP53):c.907A>G (p.Ser303Gly) | Uncertain significance | Li-Fraumeni syndrome; Hereditary cancer-predisposing syndrome |

Discussion

As already stated, OSCC is the most common tumor type of head and neck carcinomas, characterized by a high recurrence rate and poor survival of those patients. While oropharyngeal carcinomas are predominantly HPV-positive, basal-type oral cancers are mostly HPV-negative²¹. HPV-negative oral cancer patients have a significantly reduced OS¹⁷, as opposed to patients with HPV-positive cancer²². Further elucidation of the function and regulation of the *TP53*, a pivotal tumor suppressor gene, would provide advances in predicting the clinical behavior, prognosis, and chemotherapy response of HPV-negative oral cancers.

Our findings indicate that HPV-negative OSCC patients with pathogenic *TP53* mutations had a significantly lower survival rate. In the subcohort of patients who underwent cisplatin-based chemotherapy, OS was significantly shorter for those with pathogenic *TP53* mutations than those with WT *TP53*. In contrast, when all *TP53* mutations were taken into account, *TP53* mutation status was not associated with OS. These findings indicate that the OS and the resistance to platinum-based chemotherapy in OSCC could be associated with the type of *TP53* mutation and that pathogenic *TP53* mutations are a significant predictor of poor OS as opposed to benign or likely-benign mutations.

Based on the p53 mechanism of action, as one of the key cell cycle regulators after DNA damage, a number of trials investigate the association between *TP53* mutation and survival, as well as radio and chemotherapy response. Our findings of the high incidence of *TP53* mutations in HPV-negative OSCC are in accordance with previous studies, where *TP53* is mutated in approximately 50% of head and neck squamous cell carcinoma (HNSCC) cases¹. Mutations in the DNA-binding domain of *TP53* may influence individual responsiveness to chemotherapy via its ability to mediate apoptosis and cell cycle arrest¹². The most frequent genetic change in our study was *TP53* codon 72 polymorphism, but it was not associated with prognosis or chemotherapy response.

Multiple studies are demonstrating a divergent prognosis based on HPV status in OSCC patients. HPV-negative OSCCs have diverse pathological and clinical features compared to HPV-positive tumors²³. HPV-negative oral cancers are poorly differentiated tumors, and these patients had worse rates of OS compared to the HPV-positive cancers²⁴. HPV-positive HNSCCs are commonly associated with a favorable prognosis in a number of studies^{24–27}. HPV-positive head and neck tumors are predominantly driven by HPV infection, as opposed to HPV-negative tumors, which are driven by genetic mutations in *TP53* or other tumor suppressor genes, and are, therefore, characterized as tumors with poorer prognosis²⁶. The key transcriptional factors that differentiate HPV-positive and HPV-negative oral cancers are p53, AP-1, NF-kappaB, and STAT3²³. In HPV-positive HNSCC, p53 protein is generally WT, but its low levels are attributed to the HPV E6 protein activity, which targets p53 and induces its ubiquitination and degradation²⁸. This feature of HPV-positive tumors could lead to greater sensitivity to radiotherapy and radiation-induced apoptosis^{29, 30}. Clinical studies

have demonstrated that patients with HPV-negative tumors have decreased survival as opposed to HPV-positive OSCC patients³¹.

In line with our results, *TP53* mutation status associates with resistance to chemotherapy in HNSCC patients^{32–34}. The loss of function due to *TP53* mutation was associated with a low remission rate and suboptimal response to cisplatin-based neoadjuvant chemotherapy in patients with OSCC³⁴. Although HPV infection is not a predictor for surgery or the response to radiotherapy of oropharyngeal cancers³⁵, cisplatin, a standard chemotherapy regimen in head and neck cancers, is more effective in HPV-negative cells³⁶. Results of the TAX 324 (WU) trial for locally-advanced oropharyngeal cancer suggested that high-risk OSCC patients are HPV-negative and show elevated expression of β T-II or at least 2 out of 3 of the other adverse markers: GST- π , p53, and low Bcl-2. These patients have significantly decreased survival time compared to moderate-risk HPV-positive patients, who are HPV-negative but do not fulfill other criteria³⁷. The commonly recommended treatment regimen for postoperative high-risk OSCC includes the administration of cisplatin in a dosage of 100 mg/m². Cisplatin induces DNA damage and those cells should be directed to apoptosis, and p53 proapoptotic pathway is carried out through fllice-like inhibitory protein (FLIP), direct binding, and inhibition of the antiapoptotic function of Bcl-xL, enhanced expression of PTEN and AMPK inhibition³⁸.

Mutated *TP53* was previously associated with shorter OS and poor radio and chemotherapy response, which indicates its potential as a marker for a clinical course in OSCC patients. In the study of locally advanced oral cancer patients, who received cisplatin chemotherapy, patients carrying the high-risk *TP53* mutations had reduced cisplatin sensitivity and a ten times greater risk for residual disease compared to patients with low-risk mutations³⁹.

Lower response to cisplatin-based chemotherapy in patients with *TP53*-mutated tumors³² suggested the potential clinical use of p53-based therapeutics in restoring the p53 function. As a result of p53 adenoviral monotherapy or the combination with radio and chemotherapy, tumor regression was observed⁴⁰. OSCC patients carrying *TP53* mutations had a 2.7 times higher risk for cisplatin and 5-fluorouracil (5-FU)-based therapy resistance compared to patients with functional p53³³. In addition, a strong connection between nonfunctional p53 and a low response rate to cisplatin-based neoadjuvant chemotherapy was demonstrated in OSCC patients³⁴. Another potentially promising approach is treatment with small molecules that reactivate mutated p53, using PRIMA-1 (p53 Reactivation and Induction of Massive Apoptosis) as a single agent and in combination with standard chemotherapy⁴¹. PRIMA-1 therapy is more active in cell lines containing mutant p53 than WT p53 cells and results in the increased expression of p53-target genes *p21*, *Bax*, *Puma*, and *Noxa*⁴¹. Another p53 reactivating molecule RITA (Reactivation of the p53 and Induction of Tumor cell Apoptosis) induces p53 accumulation and reactivation,

promotes apoptosis via p21, BAX, and caspase-3 upregulation, and induces growth inhibition in OSCC cells *in vitro* and *in vivo* ⁴².

Conclusion

Our findings indicate that pathogenic *TP53* mutations in HPV-negative OSCC tumors could be a prognostic marker of patients' reduced OS. In addition, HPV-negative OSCC patients with the pathogenic *TP53* mutation who received cisplatin chemotherapy have a

significantly lower survival rate, indicating that the pathogenic *TP53* mutations might be a marker of chemotherapy resistance in those patients. Further elucidation of the function and regulation of *TP53* and novel therapeutic approach with small molecules that reactivate mutated *TP53* would significantly advance oral cancer therapy.

Conflict of interest

The authors declare no conflict of interest.

R E F E R E N C E S

- Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. *N Engl J Med* 2001; 345(26): 1890–900.
- Kumar D, Sharma S, Sagar V, Kumar P, Ambasta RK. Molecular signalling saga in tumour biology. *J Tumor* 2015; 18(3): 309–13.
- Petti S. Lifestyle risk factors for oral cancer. *Oral Oncol* 2009; 45(4–5): 340–50.
- Castellsagué X, Alemany L, Quer M, Halc G, Quirós B, Tous S, et al. HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. *J Natl Cancer Inst* 2016; 108(6): djv403.
- Isobe M, Emanuel BS, Givol D, Oren M, Croce CM. Localization of gene for human p53 tumour antigen to band 17p13. *Nature* 1986; 320(6057): 84–5.
- Kastan MB, Kuerbitz SJ. Control of G1 arrest after DNA damage. *Environ Health Perspect* 1993; 101(Suppl 5): 55–8.
- Zilfou JT, Lowe SW. Tumor suppressive functions of p53. *Cold Spring Harb Perspect Biol* 2009; 1(5): a001883.
- Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? *Ann Intern Med* 1969; 71(4): 747–52.
- World Health Organization. IARC TP53 Database. Lyon: International Agency for Research on Cancer; 2021. Available from: <http://p53.iarc.fr>.
- Liu XY, Pestka S, Shi YF. Recent Advances in Cancer Research and Therapy. Amsterdam, Netherlands: Elsevier; 2012. p. 700.
- Partridge M, Costea DE, Huang X. The changing face of p53 in head and neck cancer. *Int J Oral Maxillofac Surg* 2007; 36(12): 1123–38.
- Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. *Cancer Cell* 2003; 3(4): 387–402.
- Vivenga D, Monteverde M, Lattanzio L, Tonissi F, Astesana V, Denaro N, et al. Correlation of TP53 and MDM2 genotypes and clinical outcome in platinum-treated head and neck cancer patients with more than 10 years' follow-up. *Int J Biol Markers* 2016; 31(2): e183–92.
- Braakhuys BJ, Snijders PJ, Keune WJ, Meijer CJ, Ruijter-Schippers HJ, Leemans CR, et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. *J Natl Cancer Inst* 2004; 96(13): 998–1006.
- Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. *Science* 2011; 333(6046): 1157–60.
- Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. *Science* 2011; 333(6046): 1154–7.
- Iyer NG, Dogan S, Palmer F, Rahmati R, Nixon IJ, Lee N, et al. Detailed Analysis of Clinicopathologic Factors Demonstrate Distinct Difference in Outcome and Prognostic Factors Between Surgically Treated HPV-Positive and Negative Oropharyngeal Cancer. *Ann Surg Oncol* 2015; 22(13): 4411–21.
- Pérez-Palma E, Gram M, Nürnberg P, May P, Lal D. Simple ClinVar: an interactive web server to explore and retrieve gene and disease variants aggregated in ClinVar database. *Nucleic Acids Res* 2019; 47(W1): p. W99–W105.
- Westra WH. The morphologic profile of HPV-related head and neck squamous carcinoma: implications for diagnosis, prognosis, and clinical management. *Head Neck Pathol* 2012; 6 (Suppl 1): S48–54.
- Caponio VCA, Troiano G, Adipietro I, Zburakinska K, Arena C, Mangieri D, et al. Computational analysis of TP53 mutational landscape unveils key prognostic signatures and distinct pathobiological pathways in head and neck squamous cell cancer. *Br J Cancer* 2020; 123(8): 1302–14.
- Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M, et al. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. *Clin Cancer Res* 2015; 21(4): 870–81.
- Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. *J Clin Oncol* 2006; 24(5): 736–47.
- Verma G, Vishnoi K, Tyagi A, Jadli M, Singh T, Goel A, et al. Characterization of key transcription factors as molecular signatures of HPV-positive and HPV-negative oral cancers. *Cancer Med* 2017; 6(3): 591–604.
- Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. *N Engl J Med* 2010; 363(1): 24–35.
- Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. *Int J Cancer* 2007; 121(8): 1813–20.
- Ritchie JM, Smith EM, Summersgill KF, Hoffman HT, Wang D, Klussmann JP, et al. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. *Int J Cancer* 2003; 104(3): 336–44.
- Nichols AC, Faquin WC, Westra WH, Mroz EA, Begum S, Clark JR, et al. HPV-16 infection predicts treatment outcome in oropharyngeal squamous cell carcinoma. *Otolaryngol Head Neck Surg* 2009; 140(2): 228–34.
- Hafkamp HC, Manni JJ, Speel EJ. Role of human papillomavirus in the development of head and neck squamous cell carcinomas. *Acta Otolaryngol* 2004; 124(4): 520–6.

29. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx. *Cancer* 2001; 92(4): 805–13.
30. Peltenburg LT. Radiosensitivity of tumor cells. *Oncogenes and apoptosis*. *Q J Nucl Med* 2000; 44(4): 355–64.
31. Fakbry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. *J Natl Cancer Inst* 2008; 100(4): 261–9.
32. Temam S, Flahault A, Perie S, Monceaux G, Coulet F, Callard P, et al. p53 Gene Status as a Predictor of Tumor Response to Induction Chemotherapy of Patients With Locoregionally Advanced Squamous Cell Carcinomas of the Head and Neck. *J Clin Oncol* 2000; 18(2): 385–94.
33. Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier AM, Soussi T, et al. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. *J Clin Oncol* 2000; 18(7): 1465–73.
34. Perrone F, Bossi P, Cortelazzo B, Locati L, Quattrone P, Pierotti MA, et al. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. *J Clin Oncol* 2010; 28(5): 761–6.
35. Wüttekindt C, Wagner S, Sharma SJ, Würdemann N, Knuth J, Reder H, et al. HPV – A different view on Head and Neck Cancer. *Laryngorhinootologie* 2018; 97(Suppl 1): S48–S113.
36. Kim R, Lee B, Byun MR, Lee JK, Choi W. Evaluation of pemetrexed and etoposide as therapeutic regimens for human papillomavirus-positive oral and oropharyngeal cancer. *PLOS One* 2018; 13(7): e0200509.
37. Wu Y, Posner MR, Schumaker LM, Nikitakis N, Goloubeva O, Tan M, et al. Novel biomarker panel predicts prognosis in HPV-negative oropharyngeal cancer: An analysis of the TAX 324 trial (WU). *Cancer* 2012; 118(7): 1811–7.
38. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. *Eur J Pharmacol* 2014; 740: 364–78.
39. Zhou G, Liu Z, Myers JN. TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response. *J Cell Biochem* 2016; 117(12): 2682–92.
40. Tassone P, Old M, Teknos TN, Pan Q. p53-based therapeutics for head and neck squamous cell carcinoma. *Oral Oncol* 2013; 49(8): 733–7.
41. Rob JL, Kang SK, Minn I, Califan JA, Sidransky D, Koch WM. p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. *Oral Oncol* 2011; 47(1): 8–15.
42. Rob JL, Ko JH, Moon SJ, Ryu CH, Choi JY, Koch WM. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer. *Cancer Letters* 2012; 325(1): 35–41.

Received on May 25, 2020
Accepted on June 15, 2021
Online First June 2021